The Brighton Collaboration: Enhancing comparability of vaccine safety data

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 4, 2003, Pages 335-340

  Kohl, Katrin S ^a   Bonhoeffer, Jan ^b   Chen, Robert ^a   Duclos, Philippe ^c   Heijbel, Harald ^d   Heininger, Ulrich ^b   Loupi, Elisabeth ^e  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE; VACCINE;

BRAIN DISEASE; COMPARATIVE STUDY; DATA BASE; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; FEVER; GRAND MAL SEIZURE; HUMAN; IMMUNIZATION; INJECTION SITE; INTESTINE INTUSSUSCEPTION; METHODOLOGY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION; UNITED KINGDOM; VOLUNTEER;

CLINICAL TRIALS; GREAT BRITAIN; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES;

EID: 0038721208     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.851     Document Type: Note

References (30)

1. Chen RT, Pool V, Takahashi H, Weniger BG, Patel B. Combination vaccines: postlicensure safety evaluation. Clin Inf Dis 2001; 33(Suppl. 4): S327-S333.
2. Heijbel H, Jefferson T. Vaccine safety-improving monitoring. Vaccine 2001; 19: 2457-2460.
3. Hyslop DL, Read HA, Masica DN, Kotsanos JG. Pharmaceutical risk management: a call to arms for pharmacoepidemiology. Pharmacoepidemiol Drug Safe 2002; 11: 417-420.
4. Institute of Medicine. Immunization safety review: Hepatitis B vaccine and demyelinating neurological disorders. In Immunization Safety Review Committee, Stratton K, Almario D, McCormick MC (eds). The National Academy Press: Washington DC, May 2001. Available at: http://www.iom. edu/IOM/IOMHome.nsf/Pages/Hepatitis+b+report [last accessed 31 January 2003].
5. Institute of Medicine. Immunization safety review. Measles-Mumps-Rubella vaccine and autism. In Immunization Safety Review Committee, Stratton K, Gable A, Shetty P, McCormick MC (eds). The National Academy Press: Washington DC, April 2001. Available at: http://www.iom.edu/IOM/IOMHome. nsf/Pages/mmr+report [last accessed: 31 January 2003].
6. Venulet J, Bankowski Z. Harmonising adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences. Drug Safety 1998; 19: 165-172.
7. Anonymous. Canadian Communicable Disease Surveillance System. Disease-specific case definitions and surveillance methods. Canada Dis Wkly Rprt 1991; 17(Suppl. 3): 1-35.
8. World Health Organization. Supplementary information on vaccine safety, Part 2: Background rates of adverse events following immunization. WHO/V&B/00.36. Available at: http:// www.who.int/vaccines-documents/DocsPDF00/www562.pdf [last accessed: 31 January 2003].
9. Chen RT. Vaccine risks: real, perceived, and unknown. Vaccine 1999; 17: S41-S46.
10. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999; 20: 109-117.
11. International Conference on Harmonization. The medical dictionary for regulatory activities. Available at: http://www. ich.org/ichMedDRA.html [last accessed: 31 January 2003].
12. The Uppsala Monitoring Center. WHO Collaborating Centre for International Drug Monitoring: Adverse Reaction Terminology (WHO-ART). Available at: http://www.who-umc.org/pdfs/ardguide.pdf [last accessed: 31 January 2003].
13. Jacobson RM, Adegbenro A, Pankratz VS, et al. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001; 19: 2428-2433.
14. Ellenberg SS. Safety considerations for new vaccine development. Pharmacoepidemiol Drug Safe 2001; 10: 411-415.
15. VAERS. Coding symbols for a thesaurus of adverse reaction terms (COSTART). Available at: http://www.vaers.org/info.htm [last accessed: 25 February 2003].
16. Ball LK, Ball R, Kleppinger C, Kohl KS, Pratt RD. Reports to the Vaccine Adverse Event Reporting System (VAERS) of abscesses after vaccination: clinical and microbiological features of serious reports. Abstract IDSA 2001: 390.
17. Ball R, Halsey N, Braun MM, et al. VAERS Working Group. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System. J Clin Epidemiol 2002; 55: 819-824.
18. CDC. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR 2002; 51: 989-993.
19. Braun M, Terracino G, Salive , et al. Report of a US Public Health Service Workshop on HHE after pertussis immunisation. Pediatrics 1998; 102: e52.
20. CDC. Case definitions for infectious conditions under public health surveillance: Centers for Disease Control and Prevention. MMWR 1997; 46(RR-10): 1-55.
21. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). In The Cochrane Library. Issue 2. Update Software: Oxford, 2000.
22. Brown F, Greco D, Mastrantonio P, et al.(eds). Pertussis Vaccine Trials. Vol. 94. Developments in biological standardization. Basel: Karger, 1997.
23. Bonhoeffer J, Katrin K, Chen R, et al. The Brighton Collaboration: addressing the need for standardized definitions of adverse events following immunization (AEFI). Vaccine 2002; 21: 198-302.
24. Halloran ME, Longini IM, Jr. Using validation sets for outcomes and exposure to infection in vaccine field studies. Am J Epidemiol 2001; 154: 391-398.
25. The CONSORT statement and MOOSE. Available at: http://www.consort-statement.org/ [last accessed: 31 January 2003].
26. Ballew KA, Philbrick JT, Caven DE, Schorling JB. Differences in case definitions as a cause of variation in reported in-hospital CPR survival. J Gen Int Med 1994; 9: 283-285.
27. Boss LP, Toole MJ, Yip R. Assessments of mortality, morbidity, and nutritional status in Somalia during the 1991-1992 famine: recommendations for standardization of methods. JAMA 1994; 272: 371-376.
28. Hyams KC. Developing case definitions for symptom-based conditions: the problem of specificity. Epidemiol Rev 1998; 20: 148-156.
29. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-443.
30. Salmaso S, Moiraghi A, Barale A, et al. Case definitions. Dev Biol Standard 1997; 89: 135-142.